About this source
- Kind
- Research
- Design
- Human clinical trial
- Population
- 10 people with Barth syndrome entered the extension; 8 reached week 168
- Sample size
- 10
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Open-label extension with no concurrent control group, very small, with 2 participants lost by week 168. Several authors are affiliated with Stealth BioTherapeutics, the developer. Abstract read via Europe PMC; full text not read.
Cited in
Barth syndrome, 168-week extension
Elamipretide · Research finding
PreliminaryBarth syndrome extension
Elamipretide · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.